PORtopulmonary Hypertension Treatment wIth maCitentan - a randOmized Clinical Trial (PORTICO)
Primary Purpose
Portopulmonary Hypertension
Status
Completed
Phase
Phase 4
Locations
International
Study Type
Interventional
Intervention
Macitentan
Placebo
Sponsored by

About this trial
This is an interventional treatment trial for Portopulmonary Hypertension
Eligibility Criteria
Main Inclusion Criteria:
- Male or female of at least 18 years of age
- Confirmed diagnosis of portopulmonary hypertension
Main Exclusion Criteria:
- Severe hepatic impairment
- Severe obstructive or restrictive lung disease
- Pulmonary veno-occlusive disease
- Systolic blood pressure (SBP) < 90 mmHg at Screening
- ALT/AST >= 3 x ULN
- Bilirubin >= 3 mg/dL at Screening
- Any known factor or disease that might interfere with treatment compliance, study conduct, or interpretation of results
Sites / Locations
- Mayo Clinic -Clinical Studies Unit
- UCSD
- David Geffen School of Medicine, UCLA
- Keck School of Medicine
- UCSF
- University of Colorado Health Sciences Center Aurora
- University of Florida - Divison of Pulmonary Critical Care & Sleep
- University of Florida College of Medicine
- Mayo Clinic Florida - Pulmonary Dept.
- University of Miami
- South Miami Hospital
- Emory Healthcare
- Piedmont Healthcare
- Northwestern University
- Indiana University
- Kentuckiana Pulmonary Associates
- Boston University
- Henry Ford Hospital
- Mayo Clinic
- University of New Mexico Health Science Center
- University of Cincinnati
- Cleveland Clinic - Department of Cardiovascular Medicine
- University of Pennsylvania
- UPMC Montefiore
- Baylor University Medical Center
- University of Texas Southwestern Medical Center Division of NeuroCritical Care 75390-8550
- Methodist Hospital
- Methodist Hospital
- University of Wisconsin-Madison
- Servico de Hipertensao Pulmonar - Complexo Hospitalar Santa Casa Irmandade Santa de Misericordia de Porto Alegre
- Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo (HC-FMUSP)
- Lékařská fakulta a Všeobecná fakultní nemocnice v Praze, II. Interní klinika kardiologie a angiologie U
- IKEM (Institut klinické a experimentální medicíny, Institute for Clinical and Experimental Medicine)
- CHRU Hôpital Cavale Blanche Brest
- CHRU de Grenoble, Hôpital Albert Michallon
- CHU Côte de Nacre, Service de Pneumologie
- Hôpital cardiologique, Service de cardiologie 59037 Lille Cedex"
- Hôpital Cardiologique et Pneumologique Louis Pradel 69677 Bron cedex"
- Hôpital Kremlin Bicêtre Service de Pneumologie
- Hôpital Pontchaillou - CHU Rennes Service de Cardiologie et des Maladies Vasculaires Rennes Cedex 9 35033"
- CHU Rouen
- CHU Toulouse - Hôpital Larrey Hôpital de Jour et Semaine
- Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden
- Universitätsklinikum Giessen und Marburg GmbH Justus-Liebig Universität Giessen 35392
- Medizinische Hochschule Hannover, Abteilung Pneumologie
- Thoraxklinik des Universitätsklinikums Heidelberg Zentrum für pulmonale Hypertonie Studienkoordination
- Universitätsklinikum Leipzig, Department Innere Medizin, Abteilung Pneumologie
- Hospital Clinico i Provincial Servicio de Neumología
- Hospital Universitario12 Octubre
- NHS Greater Glasgow and Clyde Trust
- The Royal Free Hospital/ Cardiology Department
- Sheffield Teaching Hospitals NHS Foundation Trust Royal Hallamshire Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Investigational treatment
Placebo
Arm Description
Macitentan film-coated tablet 10 mg once daily.
Matching placebo tablet once daily.
Outcomes
Primary Outcome Measures
Relative Change From Baseline to Week 12 in Pulmonary Vascular Resistance (PVR).
The relative change from baseline to Week 12 in PVR is expressed as a ratio of Week 12 to baseline PVR.
Secondary Outcome Measures
Change From Baseline to Week 12 in 6-minute Walk Distance (6MWD)
The purpose of the six minute walk is to test exercise tolerance and capacity. The test measures the distance an individual is able to walk over a total of six minutes on a hard, flat surface. The goal is for the individual to walk as far as possible in six minutes.
Change From Baseline to Week 12 in WHO Functional Class (FC)
Changes from baseline to Week 12 in WHO FC were dichotomized as worsening (i.e., change > 0) versus no change or improvement (i.e., change ≤ 0). Class I: no symptoms with exercise or at rest. No limitation of activity. Class II: No symptoms at rest but slight limitation with ordinary activities causing symptoms (e.g. short of breath with climbing a flight of stairs, grocery shopping, or making the bed). Class III: may not have symptoms at rest but activities greatly limited by shortness of breath, fatigue, or near fainting. Class IV: symptoms at rest (e.g. dyspnea and/or fatigue) and inability to carry out any physical activity without symptoms. Patients in class IV manifest signs of right heart failure.
Change From Baseline to Week 12 in the Biomarker N-terminal Pro B-type Natriuretic Peptide (NT-proBNP)
NT-proBNP functions as a strong indicator of prognosis in patients with pulmonary hypertension (PH). The relative change from baseline to Week 12 in NT-proBNP is expressed as a ratio of Week 12 to baseline NT-proBNP.
Change From Baseline to Week 12 in Mean Right Atrial Pressure (mRAP)
mRAP is the mean blood pressure in the right atrium of the heart.
Change From Baseline to Week 12 in Mean Pulmonary Artery Pressure (mPAP)
mPAP is the mean blood pressure inside the pulmonary artery which moves the blood from the heart to the lungs. Monitoring of mPAP can detect small changes in the function of the heart.
Change From Baseline to Week 12 in Cardiac Index
The cardiac index is an assessment of the function of the heart and relates the cardiac output to the patient's body size (the patient's body surface area).
Change From Baseline to Week 12 in Total Pulmonary Resistance (TPR)
TPR is the resistance the pulmonary circulation that must be overcome in order for the blood flow to occur. It takes into account the blood pressure in the pulmonary arteries and the cardiac output. It is an important measurement to monitor the function of the pulmonary circulation and detect disease progression or improvement.
Change From Baseline to Week 12 in Mixed Venous Oxygen Saturation (SVO2)
SVO2 help assess tissue oxygen delivery. It describes the percentage of oxygen bound to hemoglobin in the blood which returns to the heart. This reflects the amount of residual oxygen in the blood after oxygen extraction by the tissues throughout the body.
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT02382016
Brief Title
PORtopulmonary Hypertension Treatment wIth maCitentan - a randOmized Clinical Trial
Acronym
PORTICO
Official Title
A Randomized, Double-blind, Placebo-controlled, Prospective, Multicenter, Parallel Group Study to Assess the Safety and Efficacy of Macitentan in Patients With Portopulmonary Hypertension
Study Type
Interventional
2. Study Status
Record Verification Date
October 2019
Overall Recruitment Status
Completed
Study Start Date
June 23, 2015 (Actual)
Primary Completion Date
October 25, 2017 (Actual)
Study Completion Date
October 31, 2018 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Actelion
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
24-week study to evaluate the efficacy and safety of macitentan for the treatment of portopulmonary hypertension.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Portopulmonary Hypertension
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
85 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Investigational treatment
Arm Type
Experimental
Arm Description
Macitentan film-coated tablet 10 mg once daily.
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Matching placebo tablet once daily.
Intervention Type
Drug
Intervention Name(s)
Macitentan
Other Intervention Name(s)
ACT-064992
Intervention Description
Macitentan film-coated tablet 10 mg once daily.
Intervention Type
Other
Intervention Name(s)
Placebo
Intervention Description
Matching placebo tablet once daily.
Primary Outcome Measure Information:
Title
Relative Change From Baseline to Week 12 in Pulmonary Vascular Resistance (PVR).
Description
The relative change from baseline to Week 12 in PVR is expressed as a ratio of Week 12 to baseline PVR.
Time Frame
From enrollment/baseline to Week 12 in the Double Blind (DB) treatment period
Secondary Outcome Measure Information:
Title
Change From Baseline to Week 12 in 6-minute Walk Distance (6MWD)
Description
The purpose of the six minute walk is to test exercise tolerance and capacity. The test measures the distance an individual is able to walk over a total of six minutes on a hard, flat surface. The goal is for the individual to walk as far as possible in six minutes.
Time Frame
From enrollment/baseline to Week 12 in the DB treatment period
Title
Change From Baseline to Week 12 in WHO Functional Class (FC)
Description
Changes from baseline to Week 12 in WHO FC were dichotomized as worsening (i.e., change > 0) versus no change or improvement (i.e., change ≤ 0). Class I: no symptoms with exercise or at rest. No limitation of activity. Class II: No symptoms at rest but slight limitation with ordinary activities causing symptoms (e.g. short of breath with climbing a flight of stairs, grocery shopping, or making the bed). Class III: may not have symptoms at rest but activities greatly limited by shortness of breath, fatigue, or near fainting. Class IV: symptoms at rest (e.g. dyspnea and/or fatigue) and inability to carry out any physical activity without symptoms. Patients in class IV manifest signs of right heart failure.
Time Frame
From enrollment/baseline to Week 12 in the DB treatment period
Title
Change From Baseline to Week 12 in the Biomarker N-terminal Pro B-type Natriuretic Peptide (NT-proBNP)
Description
NT-proBNP functions as a strong indicator of prognosis in patients with pulmonary hypertension (PH). The relative change from baseline to Week 12 in NT-proBNP is expressed as a ratio of Week 12 to baseline NT-proBNP.
Time Frame
From enrollment/baseline to Week 12 in the DB treatment period
Title
Change From Baseline to Week 12 in Mean Right Atrial Pressure (mRAP)
Description
mRAP is the mean blood pressure in the right atrium of the heart.
Time Frame
From enrollment/baseline to Week 12 in the DB treatment period
Title
Change From Baseline to Week 12 in Mean Pulmonary Artery Pressure (mPAP)
Description
mPAP is the mean blood pressure inside the pulmonary artery which moves the blood from the heart to the lungs. Monitoring of mPAP can detect small changes in the function of the heart.
Time Frame
From enrollment/baseline to Week 12 in the DB treatment period
Title
Change From Baseline to Week 12 in Cardiac Index
Description
The cardiac index is an assessment of the function of the heart and relates the cardiac output to the patient's body size (the patient's body surface area).
Time Frame
From enrollment/baseline to Week 12 in the DB treatment period
Title
Change From Baseline to Week 12 in Total Pulmonary Resistance (TPR)
Description
TPR is the resistance the pulmonary circulation that must be overcome in order for the blood flow to occur. It takes into account the blood pressure in the pulmonary arteries and the cardiac output. It is an important measurement to monitor the function of the pulmonary circulation and detect disease progression or improvement.
Time Frame
From enrollment/baseline to Week 12 in the DB treatment period
Title
Change From Baseline to Week 12 in Mixed Venous Oxygen Saturation (SVO2)
Description
SVO2 help assess tissue oxygen delivery. It describes the percentage of oxygen bound to hemoglobin in the blood which returns to the heart. This reflects the amount of residual oxygen in the blood after oxygen extraction by the tissues throughout the body.
Time Frame
From enrollment/baseline to Week 12 in the DB treatment period
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Main Inclusion Criteria:
Male or female of at least 18 years of age
Confirmed diagnosis of portopulmonary hypertension
Main Exclusion Criteria:
Severe hepatic impairment
Severe obstructive or restrictive lung disease
Pulmonary veno-occlusive disease
Systolic blood pressure (SBP) < 90 mmHg at Screening
ALT/AST >= 3 x ULN
Bilirubin >= 3 mg/dL at Screening
Any known factor or disease that might interfere with treatment compliance, study conduct, or interpretation of results
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Loïc Perchenet, PhD
Organizational Affiliation
Actelion
Official's Role
Study Director
Facility Information:
Facility Name
Mayo Clinic -Clinical Studies Unit
City
Phoenix
State/Province
Arizona
ZIP/Postal Code
85054
Country
United States
Facility Name
UCSD
City
La Jolla
State/Province
California
ZIP/Postal Code
92093
Country
United States
Facility Name
David Geffen School of Medicine, UCLA
City
Los Angeles
State/Province
California
ZIP/Postal Code
90025-1690
Country
United States
Facility Name
Keck School of Medicine
City
Los Angeles
State/Province
California
ZIP/Postal Code
90033
Country
United States
Facility Name
UCSF
City
San Francisco
State/Province
California
ZIP/Postal Code
91413-2204
Country
United States
Facility Name
University of Colorado Health Sciences Center Aurora
City
Aurora
State/Province
Colorado
ZIP/Postal Code
80045
Country
United States
Facility Name
University of Florida - Divison of Pulmonary Critical Care & Sleep
City
Gainesville
State/Province
Florida
ZIP/Postal Code
32610
Country
United States
Facility Name
University of Florida College of Medicine
City
Jacksonville
State/Province
Florida
ZIP/Postal Code
32209
Country
United States
Facility Name
Mayo Clinic Florida - Pulmonary Dept.
City
Jacksonville
State/Province
Florida
ZIP/Postal Code
32224
Country
United States
Facility Name
University of Miami
City
Miami
State/Province
Florida
ZIP/Postal Code
33136
Country
United States
Facility Name
South Miami Hospital
City
South Miami
State/Province
Florida
ZIP/Postal Code
33143
Country
United States
Facility Name
Emory Healthcare
City
Atlanta
State/Province
Georgia
ZIP/Postal Code
30322
Country
United States
Facility Name
Piedmont Healthcare
City
Austell
State/Province
Georgia
ZIP/Postal Code
30106
Country
United States
Facility Name
Northwestern University
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60611
Country
United States
Facility Name
Indiana University
City
Indianapolis
State/Province
Indiana
ZIP/Postal Code
46202
Country
United States
Facility Name
Kentuckiana Pulmonary Associates
City
Louisville
State/Province
Kentucky
ZIP/Postal Code
40202
Country
United States
Facility Name
Boston University
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02118
Country
United States
Facility Name
Henry Ford Hospital
City
Detroit
State/Province
Michigan
ZIP/Postal Code
48202
Country
United States
Facility Name
Mayo Clinic
City
Rochester
State/Province
Minnesota
ZIP/Postal Code
55905
Country
United States
Facility Name
University of New Mexico Health Science Center
City
Albuquerque
State/Province
New Mexico
ZIP/Postal Code
87131-0001
Country
United States
Facility Name
University of Cincinnati
City
Cincinnati
State/Province
Ohio
ZIP/Postal Code
45267
Country
United States
Facility Name
Cleveland Clinic - Department of Cardiovascular Medicine
City
Cleveland
State/Province
Ohio
ZIP/Postal Code
44195
Country
United States
Facility Name
University of Pennsylvania
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19104
Country
United States
Facility Name
UPMC Montefiore
City
Pittsburgh
State/Province
Pennsylvania
ZIP/Postal Code
15213
Country
United States
Facility Name
Baylor University Medical Center
City
Dallas
State/Province
Texas
ZIP/Postal Code
75226
Country
United States
Facility Name
University of Texas Southwestern Medical Center Division of NeuroCritical Care 75390-8550
City
Dallas
State/Province
Texas
ZIP/Postal Code
75390-8550
Country
United States
Facility Name
Methodist Hospital
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States
Facility Name
Methodist Hospital
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78229
Country
United States
Facility Name
University of Wisconsin-Madison
City
Madison
State/Province
Wisconsin
ZIP/Postal Code
53705-2281
Country
United States
Facility Name
Servico de Hipertensao Pulmonar - Complexo Hospitalar Santa Casa Irmandade Santa de Misericordia de Porto Alegre
City
Porto Alegre
ZIP/Postal Code
92020-090
Country
Brazil
Facility Name
Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo (HC-FMUSP)
City
Sao Paulo
ZIP/Postal Code
05403-000
Country
Brazil
Facility Name
Lékařská fakulta a Všeobecná fakultní nemocnice v Praze, II. Interní klinika kardiologie a angiologie U
City
Prague
ZIP/Postal Code
128 08
Country
Czechia
Facility Name
IKEM (Institut klinické a experimentální medicíny, Institute for Clinical and Experimental Medicine)
City
Prague
ZIP/Postal Code
140 21
Country
Czechia
Facility Name
CHRU Hôpital Cavale Blanche Brest
City
Brest
State/Province
Bretagne
ZIP/Postal Code
29609
Country
France
Facility Name
CHRU de Grenoble, Hôpital Albert Michallon
City
Grenoble
State/Province
Rhône- Alpes
ZIP/Postal Code
38043
Country
France
Facility Name
CHU Côte de Nacre, Service de Pneumologie
City
Caen
ZIP/Postal Code
14033
Country
France
Facility Name
Hôpital cardiologique, Service de cardiologie 59037 Lille Cedex"
City
Lille
ZIP/Postal Code
59037
Country
France
Facility Name
Hôpital Cardiologique et Pneumologique Louis Pradel 69677 Bron cedex"
City
Lyon
ZIP/Postal Code
69677
Country
France
Facility Name
Hôpital Kremlin Bicêtre Service de Pneumologie
City
Paris
ZIP/Postal Code
94275
Country
France
Facility Name
Hôpital Pontchaillou - CHU Rennes Service de Cardiologie et des Maladies Vasculaires Rennes Cedex 9 35033"
City
Rennes
ZIP/Postal Code
35033
Country
France
Facility Name
CHU Rouen
City
Rouen
ZIP/Postal Code
76031
Country
France
Facility Name
CHU Toulouse - Hôpital Larrey Hôpital de Jour et Semaine
City
Toulouse
ZIP/Postal Code
31059
Country
France
Facility Name
Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden
City
Dresden
ZIP/Postal Code
01307
Country
Germany
Facility Name
Universitätsklinikum Giessen und Marburg GmbH Justus-Liebig Universität Giessen 35392
City
Giessen
ZIP/Postal Code
35392
Country
Germany
Facility Name
Medizinische Hochschule Hannover, Abteilung Pneumologie
City
Hannover
ZIP/Postal Code
30625
Country
Germany
Facility Name
Thoraxklinik des Universitätsklinikums Heidelberg Zentrum für pulmonale Hypertonie Studienkoordination
City
Heidelberg
ZIP/Postal Code
69126
Country
Germany
Facility Name
Universitätsklinikum Leipzig, Department Innere Medizin, Abteilung Pneumologie
City
Leipzig
ZIP/Postal Code
04103
Country
Germany
Facility Name
Hospital Clinico i Provincial Servicio de Neumología
City
Barcelona
ZIP/Postal Code
08036
Country
Spain
Facility Name
Hospital Universitario12 Octubre
City
Madrid
ZIP/Postal Code
28041
Country
Spain
Facility Name
NHS Greater Glasgow and Clyde Trust
City
Glasgow
State/Province
Scotland
ZIP/Postal Code
G11 6NT
Country
United Kingdom
Facility Name
The Royal Free Hospital/ Cardiology Department
City
London
ZIP/Postal Code
NW3 2QG
Country
United Kingdom
Facility Name
Sheffield Teaching Hospitals NHS Foundation Trust Royal Hallamshire Hospital
City
Sheffield
ZIP/Postal Code
S10 2RX
Country
United Kingdom
12. IPD Sharing Statement
Citations:
PubMed Identifier
32031690
Citation
Raevens S, Fallon MB. PORTICO: First Randomized Controlled Trial of Vasomodulator Therapy in Portopulmonary Hypertension. Hepatology. 2020 May;71(5):1870-1872. doi: 10.1002/hep.31166. No abstract available.
Results Reference
derived
PubMed Identifier
31178422
Citation
Sitbon O, Bosch J, Cottreel E, Csonka D, de Groote P, Hoeper MM, Kim NH, Martin N, Savale L, Krowka M. Macitentan for the treatment of portopulmonary hypertension (PORTICO): a multicentre, randomised, double-blind, placebo-controlled, phase 4 trial. Lancet Respir Med. 2019 Jul;7(7):594-604. doi: 10.1016/S2213-2600(19)30091-8. Epub 2019 Jun 6.
Results Reference
derived
Learn more about this trial
PORtopulmonary Hypertension Treatment wIth maCitentan - a randOmized Clinical Trial
We'll reach out to this number within 24 hrs